Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

NCT05768321 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: GEC255 tablets

Sponsor

GenEros Biopharma Hangzhou Ltd